Thinly traded nano cap Akari Therapeutics (AKTX +10.4%) is up on more than a 6x surge in volume on the heels of interim data from a Phase 3 clinical trial, CAPSTONE, evaluating Coversin (nomacopan) in complement inhibitor naïve, transfusion-dependent paroxysmal nocturnal hemoglobinuria (PNH) patients, an Orphan Drug indication in the U.S. and Europe.
All four participants who were transfusion-dependent at study entry who received nomacopan were transfusion independent for the first six months of therapy.
All four participants who were transfusion-dependent at study entry who received standard-of-care treatment remained transfusion-dependent.
No new safety signals were observed.
Additional data will be presented in June at the European Hematology Association Annual Congress in Frankfurt.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.